Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars

Collegium Pharmaceutical reported Q3 2026 revenue of $216.3M, in line with estimates, and adjusted EPS of $1.96, beating estimates by 5.6%. The company reconfirmed its full-year revenue guidance of $840M and raised EBITDA guidance to $457.5M, above estimates. Operating margin decreased to 13.3% from 29.7% YoY.

Original reporting
Published Nov 5, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars — source image
Decision brief

The 30-second read

$COLLBullishHigh
01

Why it matters

The earnings beat and reaffirmed guidance suggest strong pipeline progress, likely attracting growth‑oriented investors.

02

Market read

Fresh earnings data provides a clear catalyst for short‑term trading decisions on COLL.

03

What to watch

Potential upcoming regulatory or clinical trial milestones could temper the rally if not met.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Collegium Pharmaceutical is a small‑cap biotech that recently released its Q3 2026 earnings.

Company-level read

Ticker impact

$COLLBullishHigh confidence
Context

Collegium Pharmaceutical reported Q3 2026 revenue of $216.3M, beating estimates, and reaffirmed full-year revenue guidance of $840M.

Expected impact

upward pressure as the market prices in the earnings beat and raised guidance

Evidence & confidence

The beat on revenue and EPS, plus higher‑than‑expected full‑year guidance, are fresh primary disclosures that typically drive buying interest.

Market effects

Biotech and specialty pharma sector may see modest uplift as the beat highlights demand for niche therapeutics.

U.S. small‑cap biotech segment could see increased buying pressure.

Limited to investors focused on U.S. biotech; no broad macro impact.

Counterpoint

If the beat is already priced in, the stock could face short‑covering pull‑back.

Key entities

  • Collegium Pharmaceutical

    U.S. listed biotech (NASDAQ:COLL) reporting Q3 2026 results.

Related articles

$COLLMedAI 8/10

Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

$COLLMed

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

$COLLMed

Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

$COLLMed

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.

$COLLLow

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Genera